Study of Zatolmilast (BPN14770) in Participants With PPP2R5D Neurodevelopmental Disorder (Jordan's Syndrome [JS])
A Phase 2 Randomized, Double-blind, Placebo-controlled, Study of Zatolmilast (BPN14770) in Subjects With PPP2R5D Neurodevelopmental Disorder (Jordan's Syndrome)
Sponsor: Shionogi
This PHASE2 trial investigates Jordan's Syndrome and PPP2R5D Neurodevelopmental Disorder and is currently ongoing. Shionogi leads this study, which shows 5 recorded versions since 2025 — indicating limited longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.
Status Flow
Change History
5 versions recorded-
Feb 2026 — Present [monthly]
Active Not Recruiting PHASE2
Status: Enrolling By Invitation → Active Not Recruiting
-
Aug 2025 — Feb 2026 [monthly]
Enrolling By Invitation PHASE2
Status: Not Yet Recruiting → Enrolling By Invitation
-
Apr 2025 — Aug 2025 [monthly]
Not Yet Recruiting PHASE2
-
Feb 2025 — Apr 2025 [monthly]
Not Yet Recruiting PHASE2
-
Jan 2025 — Feb 2025 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Shionogi
For direct contact, visit the study record on ClinicalTrials.gov .